skip to Global Navigation Bar skip to main content

homeHome > About Us > Press Release > News


News Content
Daewoong Pharmaceutical ‘Nabota’ enters phase 3 clinical studies in China during the second half.
Date 2019-03-13 Hit 1182
News List
Prev Daewoong Pharmaceutical selected for government funding for DWN12088, a new medication for pulmonary fibrosis.
Next Daewoong Pharmaceutical has released ‘Olomax’ for both hypertension and hyperlipidemia